Trials Sponsors Conditions Drugs Pricing

Conditions

Colo-rectal Cancer

Outcome Measures

Primary Outcomes (2)

Part 1 - Safety and tolerability of varsetatug masetecan in combination with bevacizumab + 5-FU + leucovorin
The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level
27 months
Part 2 - Progression-free survival (PFS) based on blinded independent central review (BICR)
PFS defined as the time from participant allocation to a trial intervention to the first documentation of objective disease progression, as determined by BICR according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause, whichever occurs first
27 months

Secondary Outcomes (6)

Objective Response Rate (ORR)
27 months
Disease Control Rate (DCR)
27 months
PFS based on Investigator assessment
27 months
Overall Survival (OS)
27 months
Duration of Response (DOR)
27 months
+1 more secondary outcomes

Study Arms (2)

varsetatug masetecan + bevacizumab + 5-FU + leucovorin

EXPERIMENTAL

Drug: varsetatug masetecanDrug: bevacizumab + 5-FU + leucovorin

varsetatug masetecan + bevacizumab

EXPERIMENTAL

Drug: varsetatug masetecanDrug: bevacizumab

Interventions

varsetatug masetecanDrug

Investigational Product

varsetatug masetecan + bevacizumabvarsetatug masetecan + bevacizumab + 5-FU + leucovorin

bevacizumab + 5-FU + leucovorinDrug

IV infusion

varsetatug masetecan + bevacizumab + 5-FU + leucovorin

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
bevacizumab + 5-FU + leucovorin
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Histologically or cytologically documented unresectable metastatic CRC
Documented progression during or following exactly one prior regimen of systemic therapy with or without targeted therapy for metastatic CRC

Sponsors & Collaborators

CytomX Therapeutics
Industrylead

MeSH Terms

Conditions

Colonic Neoplasms

Interventions

BevacizumabFluorouracilLeucovorin

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Study Officials

Monika Vainorius, MD
CytomX Therapeutics
STUDY DIRECTOR

Central Study Contacts

Karen Deane

CONTACT

650-515-3185 ClinicalTrials@cytomx.com

Study Design

Study Type: interventional
Phase: phase 1 2
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: SEQUENTIAL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

October 21, 2026

First Posted

October 28, 2026

Study Start

December 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Primary Completion

February 2029

Estimated

Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (6)

Study Arms (2)

varsetatug masetecan + bevacizumab + 5-FU + leucovorin

varsetatug masetecan + bevacizumab

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (6)

Study Arms (2)

varsetatug masetecan + bevacizumab + 5-FU + leucovorin

varsetatug masetecan + bevacizumab

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Data Sharing

Source record